Deferoxamine
(IDDIJAWJANBQLJ-UHFFFAOYSA-N)
Structure
- SMILES
- CS(=O)(=O)O.NCCCCCN(C(=O)CCC(=O)NCCCCCN(C(=O)CCC(=O)NCCCCCN(C(=O)C)O)O)O
- Molecular Formula:
- C26H52N6O11S
- Molecular Weight:
- 656.790
- Log P:
- 2.9890
- Hydrogen Bond Acceptor:
- 17
- Hydrogen Bond Donor:
- 7
- TPSA:
- 268.59
- CAS Number(s):
- 138-14-7
Synonym(s)
1.
Deferoxamine
2.
Desferrioxamine
3.
Deferoxamine B
4.
Deferoxamine Mesilate
5.
Deferoxamine Mesylate
6.
Deferoxamine Methanesulfonate
7.
Deferoximine
8.
Deferrioxamine B
9.
Desferal
10.
Desferioximine
11.
Desferrioxamine B
12.
Desferrioxamine B Mesylate
13.
Desferroxamine
14.
Mesilate, Deferoxamine
15.
Mesylate, Deferoxamine
16.
Mesylate, Desferrioxamine B
17.
Methanesulfonate, Deferoxamine
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Fundoscopy abnormal | FAERS: 18 | US FAERS | |
| 2 | Drug exposure during pregnancy | FAERS: 14 | US FAERS | |
| 3 | Drug ineffective | FAERS: 14 Canada Vigilance: 13 | Canada Vigilance US FAERS | |
| 4 | Pneumonia | FAERS: 12 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 5 | Injection site pain | FAERS: 11 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 6 | Blindness | FAERS: 10 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 7 | Diabetes Mellitus | FAERS: 10 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 8 | Vomiting | FAERS: 10 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 9 | Pain | FAERS: 9 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 10 | Deafness | FAERS: 8 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 11 | Iron Overload | FAERS: 8 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | Ototoxicity | FAERS: 8 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 13 | Blood iron increased | FAERS: 7 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 14 | Infection | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 15 | Injection site erythema | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 16 | Nausea | FAERS: 7 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 17 | Optic Neuropathy | FAERS: 7 | US FAERS | |
| 18 | Spinal X-ray abnormal | FAERS: 7 | US FAERS | |
| 19 | Urticaria | FAERS: 7 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 20 | Macular degeneration | FAERS: 6 | US FAERS | |
| 21 | Malaise | FAERS: 6 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 22 | Osteoporosis | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 23 | Retinal Vascular Disorder | FAERS: 6 | US FAERS | |
| 24 | Visual Impairment | FAERS: 6 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 25 | Abdominal Pain | FAERS: 5 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 26 | Blood creatinine increased | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 27 | Cataract | FAERS: 5 | US FAERS | |
| 28 | Constipation | FAERS: 5 | US FAERS | |
| 29 | Deafness Neurosensory | FAERS: 5 | US FAERS | |
| 30 | Hypersensitivity | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 31 | MYELODYSPLASTIC SYNDROME | FAERS: 5 | US FAERS | |
| 32 | Neutropenia | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 33 | Overdose | FAERS: 5 | US FAERS | |
| 34 | Retinogram abnormal | FAERS: 5 | US FAERS | |
| 35 | Arthralgia | FAERS: 4 | US FAERS | |
| 36 | Cellulitis | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 37 | Cerebrovascular accident | FAERS: 4 | US FAERS | |
| 38 | Disease Progression | FAERS: 4 | US FAERS | |
| 39 | Drug exposure before pregnancy | FAERS: 4 | US FAERS | |
| 40 | Erythema | FAERS: 4 Canada Vigilance: 7 | Canada Vigilance US FAERS | |
| 41 | Infusion site pain | FAERS: 4 | US FAERS | |
| 42 | Klebsiella sepsis | FAERS: 4 | US FAERS | |
| 43 | Ocular Toxicity | FAERS: 4 | US FAERS | |
| 44 | Pruritus | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 45 | Septic Shock | FAERS: 4 | US FAERS | |
| 46 | Tinnitus | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 47 | Transaminases increased | FAERS: 4 | US FAERS | |
| 48 | Vasculitis | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 49 | Asthenia | FAERS: 3 | US FAERS | |
| 50 | Blood glucose increased | FAERS: 3 | US FAERS | |
| 51 | Chills | FAERS: 3 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 52 | Concomitant disease aggravated | FAERS: 3 | US FAERS | |
| 53 | Fatigue | FAERS: 3 | US FAERS | |
| 54 | Feeling abnormal | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 55 | Hepatitis | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 56 | Hepatomegaly | FAERS: 3 | US FAERS | |
| 57 | Hypotension | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 58 | Infusion site erythema | FAERS: 3 | US FAERS | |
| 59 | Injection site infection | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 60 | Injection site inflammation | FAERS: 3 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 61 | Injection site warmth | FAERS: 3 | US FAERS | |
| 62 | Medication Error | FAERS: 3 | US FAERS | |
| 63 | Myocardial Infarction | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 64 | Optic Atrophy | FAERS: 3 | US FAERS | |
| 65 | Pulmonary Embolism | FAERS: 3 | US FAERS | |
| 66 | Respiratory distress | FAERS: 3 | US FAERS | |
| 67 | Scotoma | FAERS: 3 | US FAERS | |
| 68 | Sepsis | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 69 | Syncope | FAERS: 3 | US FAERS | |
| 70 | Tachycardia | FAERS: 3 | US FAERS | |
| 71 | Tenosynovitis | FAERS: 3 | US FAERS | |
| 72 | Alanine Aminotransferase Increased | FAERS: 2 | US FAERS | |
| 73 | Altered state of consciousness | FAERS: 2 | US FAERS | |
| 74 | Anal erosion | FAERS: 2 | US FAERS | |
| 75 | Angiomyolipoma | FAERS: 2 | US FAERS | |
| 76 | Apparent death | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 77 | Bacterial sepsis | FAERS: 2 | US FAERS | |
| 78 | Blood iron decreased | FAERS: 2 | US FAERS | |
| 79 | Cardiac Arrest | FAERS: 2 | US FAERS | |
| 80 | Cardiomegaly | FAERS: 2 | US FAERS | |
| 81 | Chromaturia | FAERS: 2 | US FAERS | |
| 82 | Deep Vein Thrombosis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 83 | Dehydration | FAERS: 2 | US FAERS | |
| 84 | Escherichia infection | FAERS: 2 | US FAERS | |
| 85 | Fluid overload | FAERS: 2 | US FAERS | |
| 86 | Flushing | FAERS: 2 | US FAERS | |
| 87 | Gastroenteritis | FAERS: 2 | US FAERS | |
| 88 | General physical health deterioration | FAERS: 2 | US FAERS | |
| 89 | Headache | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 90 | Hypophagia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 91 | Hypoxia | FAERS: 2 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 92 | Influenza | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 93 | Infusion site induration | FAERS: 2 | US FAERS | |
| 94 | Injection Site Reaction | FAERS: 2 Canada Vigilance: 12 | Canada Vigilance US FAERS | |
| 95 | Injection site urticaria | FAERS: 2 | US FAERS | |
| 96 | Leukocytosis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 97 | Lymphoma | FAERS: 2 | US FAERS | |
| 98 | Mental status changes | FAERS: 2 | US FAERS | |
| 99 | Metabolic acidosis | FAERS: 2 | US FAERS | |
| 100 | Metallosis of globe | FAERS: 2 | US FAERS | |
| 101 | Mucormycosis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 102 | Myositis | FAERS: 2 | US FAERS | |
| 103 | Nephrolithiasis | FAERS: 2 | US FAERS | |
| 104 | Neutrophil count decreased | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 105 | Optic Neuritis | FAERS: 2 | US FAERS | |
| 106 | Ossicle disorder | FAERS: 2 | US FAERS | |
| 107 | Pancytopenia | FAERS: 2 | US FAERS | |
| 108 | Paresis | FAERS: 2 | US FAERS | |
| 109 | Peritonitis | FAERS: 2 | US FAERS | |
| 110 | Pharmaceutical product complaint | FAERS: 2 | US FAERS | |
| 111 | Pregnancy | FAERS: 2 | US FAERS | |
| 112 | Procedural complication | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 113 | Product compounding quality issue | FAERS: 2 | US FAERS | |
| 114 | Product use in unapproved indication | FAERS: 2 | US FAERS | |
| 115 | Pulmonary Hypertension | FAERS: 2 | US FAERS | |
| 116 | Pulmonary toxicity | FAERS: 2 | US FAERS | |
| 117 | Respiratory Failure | FAERS: 2 | US FAERS | |
| 118 | Restrictive pulmonary disease | FAERS: 2 | US FAERS | |
| 119 | Retinal toxicity | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 120 | Sinusitis | FAERS: 2 | US FAERS | |
| 121 | Skin reaction | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 122 | Subcutaneous Abscess | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 123 | Swelling | FAERS: 2 | US FAERS | |
| 124 | Thrombocytopenia | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 125 | Thrombosis | FAERS: 2 | US FAERS | |
| 126 | White blood cell count decreased | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 127 | Wrong technique in drug usage process | FAERS: 2 | US FAERS | |
| 128 | Abdominal Abscess | FAERS: 1 | US FAERS | |
| 129 | Accidental exposure to product | FAERS: 1 | US FAERS | |
| 130 | Acquired Immunodeficiency Syndrome | FAERS: 1 | US FAERS | |
| 131 | Activities of daily living impaired | FAERS: 1 | US FAERS | |
| 132 | Anaphylactic shock | FAERS: 1 | US FAERS | |
| 133 | Angina Pectoris | FAERS: 1 | US FAERS | |
| 134 | Angiogram retina abnormal | FAERS: 1 | US FAERS | |
| 135 | Anorexia | FAERS: 1 | US FAERS | |
| 136 | Aphasia | FAERS: 1 | US FAERS | |
| 137 | Application site inflammation | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 138 | Arthropathy | FAERS: 1 | US FAERS | |
| 139 | Aspartate Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 140 | Asthma | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 141 | Atrial Flutter | FAERS: 1 | US FAERS | |
| 142 | Audiogram abnormal | FAERS: 1 | US FAERS | |
| 143 | Blood alkaline phosphatase increased | FAERS: 1 | US FAERS | |
| 144 | Blood amylase increased | FAERS: 1 | US FAERS | |
| 145 | Blood copper decreased | FAERS: 1 | US FAERS | |
| 146 | Blood creatine phosphokinase increased | FAERS: 1 | US FAERS | |
| 147 | Blood creatinine abnormal | FAERS: 1 | US FAERS | |
| 148 | Blood lactate dehydrogenase increased | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 149 | Blood potassium increased | FAERS: 1 | US FAERS | |
| 150 | Blood sodium decreased | FAERS: 1 | US FAERS | |
| 151 | Blood urea increased | FAERS: 1 | US FAERS | |
| 152 | Bone marrow transplant rejection | FAERS: 1 | US FAERS | |
| 153 | Bone pain | FAERS: 1 | US FAERS | |
| 154 | Burning sensation | FAERS: 1 | US FAERS | |
| 155 | Cardiovascular insufficiency | FAERS: 1 | US FAERS | |
| 156 | Catheter site infection | FAERS: 1 | US FAERS | |
| 157 | Cholecystitis infective | FAERS: 1 | US FAERS | |
| 158 | Cholecystitis | FAERS: 1 | US FAERS | |
| 159 | Chorioretinal atrophy | FAERS: 1 | US FAERS | |
| 160 | Cyanosis | FAERS: 1 | US FAERS | |
| 161 | Depressed Level of Consciousness | FAERS: 1 | US FAERS | |
| 162 | Device malfunction | FAERS: 1 | US FAERS | |
| 163 | Device related sepsis | FAERS: 1 | US FAERS | |
| 164 | Diabetic Nephropathy | FAERS: 1 | US FAERS | |
| 165 | Discomfort | FAERS: 1 | US FAERS | |
| 166 | Dizziness | FAERS: 1 | US FAERS | |
| 167 | Drug administration error | FAERS: 1 | US FAERS | |
| 168 | Drug dispensing error | FAERS: 1 | US FAERS | |
| 169 | Drug withdrawal syndrome | FAERS: 1 | US FAERS | |
| 170 | Duodenal Ulcer | FAERS: 1 | US FAERS | |
| 171 | Dyschromatopsia | FAERS: 1 | US FAERS | |
| 172 | Eczema | FAERS: 1 | US FAERS | |
| 173 | Ejection Fraction Decreased | FAERS: 1 | US FAERS | |
| 174 | Encephalitis | FAERS: 1 | US FAERS | |
| 175 | Eosinophilic Pneumonia | FAERS: 1 | US FAERS | |
| 176 | Epistaxis | FAERS: 1 | US FAERS | |
| 177 | Escherichia urinary tract infection | FAERS: 1 | US FAERS | |
| 178 | Exophthalmos | FAERS: 1 | US FAERS | |
| 179 | Fracture | FAERS: 1 | US FAERS | |
| 180 | Full blood count decreased | FAERS: 1 | US FAERS | |
| 181 | Growth retardation | FAERS: 1 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 182 | Haptoglobin Decreased | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 183 | Hepatitis B antigen positive | FAERS: 1 | US FAERS | |
| 184 | Hepatitis C virus test | FAERS: 1 | US FAERS | |
| 185 | Hepatitis C | FAERS: 1 | US FAERS | |
| 186 | Hepatorenal Syndrome | FAERS: 1 | US FAERS | |
| 187 | Hepatosplenomegaly | FAERS: 1 | US FAERS | |
| 188 | Hypoaesthesia facial | FAERS: 1 | US FAERS | |
| 189 | Incorrect drug administration rate | FAERS: 1 | US FAERS | |
| 190 | Incorrect route of product administration | FAERS: 1 | US FAERS | |
| 191 | Infectious peritonitis | FAERS: 1 | US FAERS | |
| 192 | Inflammatory marker increased | FAERS: 1 | US FAERS | |
| 193 | Infusion site abscess | FAERS: 1 | US FAERS | |
| 194 | Injection site cellulitis | FAERS: 1 | US FAERS | |
| 195 | Injection site scar | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 196 | Iritis | FAERS: 1 | US FAERS | |
| 197 | Laparoscopy | FAERS: 1 | US FAERS | |
| 198 | Leukocytoclastic vasculitis | FAERS: 1 | US FAERS | |
| 199 | Leukopenia | FAERS: 1 | US FAERS | |
| 200 | Lip swelling | FAERS: 1 | US FAERS | |
| 201 | Liver Abscess | FAERS: 1 | US FAERS | |
| 202 | Local reaction | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 203 | Lower respiratory tract infection | FAERS: 1 | US FAERS | |
| 204 | Medical device pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 205 | Meningioma | FAERS: 1 | US FAERS | |
| 206 | Musculoskeletal discomfort | FAERS: 1 | US FAERS | |
| 207 | Myalgia | FAERS: 1 | US FAERS | |
| 208 | Nasal mucosal disorder | FAERS: 1 | US FAERS | |
| 209 | Neutrophil percentage decreased | FAERS: 1 | US FAERS | |
| 210 | Nocardia sepsis | FAERS: 1 | US FAERS | |
| 211 | Nodule | FAERS: 1 | US FAERS | |
| 212 | Obstruction | FAERS: 1 | US FAERS | |
| 213 | Occult blood positive | FAERS: 1 | US FAERS | |
| 214 | Oropharyngeal pain | FAERS: 1 | US FAERS | |
| 215 | Osteolysis | FAERS: 1 | US FAERS | |
| 216 | PO2 decreased | FAERS: 1 | US FAERS | |
| 217 | Pachymeningitis | FAERS: 1 | US FAERS | |
| 218 | Papule | FAERS: 1 | US FAERS | |
| 219 | Parathyroidectomy | FAERS: 1 | US FAERS | |
| 220 | Peripheral pulse decreased | FAERS: 1 | US FAERS | |
| 221 | Phlebitis | FAERS: 1 | US FAERS | |
| 222 | Poisoning | FAERS: 1 | US FAERS | |
| 223 | Portal Hypertension | FAERS: 1 | US FAERS | |
| 224 | Portal Vein Thrombosis | FAERS: 1 | US FAERS | |
| 225 | Pre-Eclampsia | FAERS: 1 | US FAERS | |
| 226 | Product label issue | FAERS: 1 | US FAERS | |
| 227 | Product quality issue | FAERS: 1 | US FAERS | |
| 228 | Purpura | FAERS: 1 | US FAERS | |
| 229 | Purulent discharge | FAERS: 1 | US FAERS | |
| 230 | Pyelonephritis | FAERS: 1 | US FAERS | |
| 231 | Quadriplegia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 232 | Renal Colic | FAERS: 1 | US FAERS | |
| 233 | Renal tubular atrophy | FAERS: 1 | US FAERS | |
| 234 | Renal tubular disorder | FAERS: 1 | US FAERS | |
| 235 | Retinal Detachment | FAERS: 1 | US FAERS | |
| 236 | Retinal pigment epitheliopathy | FAERS: 1 | US FAERS | |
| 237 | Retinal pigmentation | FAERS: 1 | US FAERS | |
| 238 | Rhabdomyolysis | FAERS: 1 | US FAERS | |
| 239 | Septic embolus | FAERS: 1 | US FAERS | |
| 240 | Sickle Cell Trait | FAERS: 1 | US FAERS | |
| 241 | Skin irritation | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 242 | Skin lesion | FAERS: 1 | US FAERS | |
| 243 | Skin necrosis | FAERS: 1 | US FAERS | |
| 244 | Splenectomy | FAERS: 1 | US FAERS | |
| 245 | Splenic Infarction | FAERS: 1 | US FAERS | |
| 246 | Splenomegaly | FAERS: 1 | US FAERS | |
| 247 | Stem cell transplant | FAERS: 1 | US FAERS | |
| 248 | Toxic Epidermal Necrolysis | FAERS: 1 | US FAERS | |
| 249 | Toxicity to various agents | FAERS: 1 | US FAERS | |
| 250 | Tuberculosis | FAERS: 1 | US FAERS | |
| 251 | Urinary tract infection | FAERS: 1 | US FAERS | |
| 252 | Urine output increased | FAERS: 1 | US FAERS | |
| 253 | Visual disturbance | FAERS: 1 | US FAERS | |
| 254 | Weight decreased | FAERS: 1 | US FAERS | |
| 255 | Wound Complication | FAERS: 1 | US FAERS | |
| 256 | Zygomycosis | FAERS: 1 | US FAERS | |
| 257 | Abscess | Canada Vigilance: 1 | Canada Vigilance | |
| 258 | Anaphylactoid Reaction | Canada Vigilance: 2 | Canada Vigilance | |
| 259 | Chest Pain | Canada Vigilance: 1 | Canada Vigilance | |
| 260 | Creatinine renal clearance decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 261 | Drug level increased | Canada Vigilance: 1 | Canada Vigilance | |
| 262 | Infusion site cellulitis | Canada Vigilance: 1 | Canada Vigilance | |
| 263 | Injection site mass | Canada Vigilance: 1 | Canada Vigilance | |
| 264 | Injection site nodule | Canada Vigilance: 1 | Canada Vigilance | |
| 265 | Skin Induration | Canada Vigilance: 1 | Canada Vigilance | |
| 266 | Skin test positive | Canada Vigilance: 2 | Canada Vigilance | |
| 267 | Wheezing | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.